Last spring, we had the opportunity to work with a group of founders following a medtech pitch event in Chicago. As part of that engagement, we offered pitch deck reviews: a chance to sit down with early-stage companies and give honest, outside feedback on how they were telling their story to investors.
One of those founders was building a medical device company. At the end of his review, he asked us a question we hadn’t been asked before — and it stopped us cold.
“Why do investors say no?”
It’s the essential question. The one underneath every pitch, every rejection, every founder who walks out of a meeting not knowing what went wrong. And yet no one had put it to us quite so directly before.
What follows is our answer.
1. You’re Pitching the Wrong Investor
Before a single slide is reviewed, many pitches are dead on arrival—not because of the science or the team, but because the founder is in the wrong room.
Every venture capital firm has a thesis: a defined focus on stage, sector, technology type, and check size. A fund focused on late-stage, revenue-generating companies isn’t going to back your pre-clinical device. A deep oncology portfolio isn’t the right first call for a primary care diagnostic.
This sounds obvious. But founders often get so focused on getting meetings that they don’t stop to ask whether the investor across the table is actually positioned to say yes.
Pitching the wrong investor doesn’t just cost you a meeting. It signals that you don’t yet understand your market or how the funding ecosystem works.
2. Your Market Opportunity Doesn’t Hold Up
Investors need to believe in the size of the opportunity before they believe in the solution. And in life sciences and medtech, this is where a lot of pitches quietly fall apart.
The most common mistake isn’t underselling the market — it’s overselling it in ways that don’t hold up to scrutiny. Citing a massive global market figure without a realistic path to capturing any meaningful share tells an experienced investor nothing. What they want to see is a credible picture of your actual addressable market: the specific patients, procedures, care settings, or customers you can realistically reach.
For devices and therapies moving through prescribers, clinicians, or hospital systems, that means showing a reimbursement strategy. How will this be paid for? What does the path to payer adoption look like? Investors who know this space will ask. If your pitch doesn’t answer it, your market size number becomes meaningless.
Competitive landscape matters too. Investors want to know what else addresses the same problem and why your approach is meaningfully better. A founder who can map the landscape clearly and articulate their differentiation with specificity signals market fluency. One who can’t raises questions about whether they fully understand the space they’re entering.
3. Your Team Has Gaps — Especially on the Commercial Side
Investors aren’t just betting on science. They’re betting on the people who will execute it, through regulatory hurdles, reimbursement battles, and eventually, a market launch.
The gap we see most often isn’t scientific. Most life science and medtech founders have deep technical credentials. What’s frequently missing is commercial, regulatory, or operational experience — the people who know how to move a product through the FDA, build a sales strategy, or manage a board.
This doesn’t mean you need a full executive team at Series A. It means showing that you know what you don’t know and that you’ve surrounded yourself with advisors or key hires who fill those gaps credibly.
4. Your Regulatory Pathway Is Weak
In life sciences and medtech, regulatory strategy isn’t a detail. It’s a fundamental part of your business model — and when a pitch glosses over it, investors notice.
We see two failure modes. The first is omission: no mention of regulatory pathway at all. The second is vagueness: a single slide that says “510(k) pathway” or “BLA filing” with no timeline, no rationale, and no acknowledgment of the hurdles involved.
Regulatory strategy also means clinical evidence strategy. What data will you need to demonstrate safety and efficacy? What does your clinical development plan look like, and how does your current evidence support the path forward? Investors are evaluating not just whether your science works, but whether you have a credible plan to prove it in the way regulators — and ultimately payers — will require.
A strong regulatory section in a pitch deck doesn’t need to be exhaustive. But it does need to demonstrate that you understand the path, the timeline, the evidence requirements, and the risks.
5. The Biggest Reason: You Haven’t Told a Story
All of the reasons above are real. All of them will get a pitch rejected. But in our experience, the most common thread running through failed life science and medtech pitches is simpler and more fundamental than any of them: the story gap.
Scientists are trained to communicate data-first: precise, objective, sequential. It’s the language of peer review, of grant applications, of lab meetings. It’s exactly the wrong language for a pitch room.
Investors aren’t evaluating a paper. They’re making a bet on a problem worth solving, a team worth backing, and a future worth funding. That decision is made faster than most founders realize, and it’s made as much on instinct and emotion as on evidence. Data validates. Story persuades.
This isn’t about dumbing down your science or dressing it up with emotion it doesn’t earn. It’s about structuring your pitch so that your audience can actually absorb it. The brain doesn’t receive data and then feel. It feels first, and then engages with data. Story creates that opening. It provides that context that makes people care, and the structure that supports understanding.
People don’t invest in molecules and mechanisms. They invest in outcomes, in potential, in a story they want to be part of.
Your science got you to the room. Your story is what gets you funded.
Do you have a story to tell? Talk to us! We’d love to hear it.